Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ET
Company Participants
Juli Miller - Investor Relations
Adrian Rawcliffe - Chief Executive Officer
Gavin Wood - Chief Financial Officer
Dennis Williams - Head of Late Stage Development
Cintia Piccina - Chief Commercial Officer
John Lunger - Chief Patient Supply Officer
Elliot Norry - Chief Medical Officer
Conference Call Participants
Jonathan Chang - Leerink Partners
Marc Frahm - TD Cowen
Tony Butler - Rodman & Renshaw
Graig Suvannavejh - Mizuho Securities
Arthur He - H.C. Wainwright
Peter Lawson - Barclays
Operator
Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call.
I would now like to turn the meeting over to Ms. Juli Miller. Please go ahead, Ms. Miller.
Juli Miller
Good morning, and welcome to our conference call to discuss our first quarter 2024 financial results and business updates.
I would ask you to review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC.
Adrian Rawcliffe, our Chief Executive Officer, is here with me for the prepared portion of the call, and other members of our management team will be available for Q&A.
With that, I'll turn the call over to Adrian. Ad?
Adrian Rawcliffe
Thanks, Juli, and thanks, everyone, for joining us for our Q1 call.
I plan to provide some brief comments before we go into Q&A. The comments are going to be brief because a couple of weeks ago, we held an Investor Day and we provided a fairly comprehensive update on the regulatory status of afami-cel as we move towards the PDUFA date of 4th of August. And we also talked about how important this is for the field as the first approved engineered TCR T-cell therapy for solid tumor indication.
We also discussed our preparations for the commercial launch of afami-cel in some detail. We said that we'd be ready to do this on approval of afami-cel, and that this would be the beginning of a commercial sarcoma franchise that we feel has significant and underappreciated value. In this morning's press release, we provided a further update on the BLA progress, and our Head of Late Stage Development, Dennis Williams, is here for the Q&A portion of this call.